rs1625579

A case-control study in 506 Han Chinese schizophrenia patients and 522 healthy controls found no significant association between microRNA-137 SNP rs1625579 and schizophrenia (P > 0.05). Meta-analysis across three Han Chinese studies showed the T allele was not associated with schizophrenia risk (pooled OR 1.087, 95% CI 0.847–1.396, P = 0.512), contradicting earlier GWAS findings.

This functional study investigated neurophysiologic effects of genome-wide association study (GWAS)-derived schizophrenia (SCZ) and bipolar disorder (BPD) risk variants in 199 patients with psychotic illness and 74 healthy controls. The SCZ risk allele (G) at TCF4 rs17512836 showed significant association with reduced auditory P3 amplitude (P=0.00017) and delayed P3 latency (P=0.005), suggesting a mechanism involving compromised attention and working memory capacity in psychotic disorders.

A comprehensive review of the genetics and epigenetics of schizophrenia, covering candidate gene associations, genome-wide association studies (GWAS), gene expression studies, and epigenetic mechanisms. The review highlights major GWAS findings including associations with CSMD1 (rs10503253), CACNA1C (rs4765905), SLC30A3 (rs11126936, rs11126929), VRK2 (rs2312147), MPC2 (rs10489202), miR-137 (rs1625579), and MKL1 (rs6001946), while discussing the complex polygenic architecture of the disorder with heritability estimated at 81-85%.

This comprehensive review examines the genomics of schizophrenia and pharmacogenomics of antipsychotic drugs, synthesizing evidence on over 200 genes associated with psychotic disorders. The authors discuss five categories of genes relevant to antipsychotic response: disease-associated genes, mechanism-of-action genes, drug metabolism genes (particularly CYP2D6, CYP2C19, CYP2C9, CYP3A4), drug transporter genes, and pleiotropic genes. The review details pharmacogenomic profiles of 20+ antipsychotic drugs and demonstrates significant ethnic and interindividual variation in drug metabolism phenotypes, with examples including CYP2D6 extensive metabolizers (55.71% of population), intermediate metabolizers (34.7%), poor metabolizers (2.28%), and ultra-rapid metabolizers (7.31%).

This review comprehensively summarizes the latest genetic studies on schizophrenia, including family studies (heritability ~80%), genome-wide association studies, epigenetic mechanisms, candidate gene investigations, and next-generation sequencing findings. Key GWAS findings identified 108 schizophrenia-associated loci including variants in MIR137 (rs1625579), TCF4 (rs12966547), CSMD1 (rs10503253), CACNA1C (rs4765905), ANK3 (rs10761482), and MHC region variants, with evidence for polygenetic inheritance involving both common SNPs and rare copy number variations.

This narrative review examines the role of microRNAs (miRNAs) in neuropsychiatric disorders including schizophrenia, bipolar disorder, major depression, Alzheimer's disease, and Parkinson's disease. The paper synthesizes studies on miRNA expression alterations in peripheral tissues and genetic variants in miRNA-related genes (SNPs in miRNAs, miRNA target genes, and miRNA processing genes), highlighting the potential of miRNAs as biomarkers for diagnosis and prognosis of brain diseases.